Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Post by frankmanon Nov 14, 2024 3:31pm
25 Views
Post# 36313430

Broke another million share day

Broke another million share day
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr
     ATS 76.0 0.065 · 0.07 21.3 0.07     1,141.7 71 100
CSE - C 76.0 0.065 · 0.07 21.3 0.07     722.9 45 48
NEO ATS - U   0.065 -0.005 -7.1 3.0 0 2
Omega - O   0.065 -0.005 -7.1 253.0 15 31
Chi-X - X   0.065 -0.005 -7.1 6.0 0 2
CX2 - H   0.065 -0.005 -7.1 126.0 8 11
CXD - D   0.0625 -0.0075 -10.7 4.8 0 3
TriAct - M   0.07     26.0 2 3

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities